Agreed definitions and a shared vision for new standards in stroke recovery research: The Stroke Recovery and Rehabilitation Roundtable taskforce:

Abstract: Abstract Background Stroke represents the second most common cause of death worldwide and a significant cause of long-term morbidity. Although the brain is incapable of regeneration, the element selenium (Se) has been found to have a role in regenerating the antioxidant systems and improving cell proliferation and viability. So, we conduct this systematic review and meta-analysis to assess its effectiveness in enhancing cell proliferation and viability. Aims Our study aims to determine the efficacy and safety of selenium in alleviating the impact of brain injury and promoting recovery in patients with stroke. Summary of review We finally included five randomized clinical trials. Our meta-analysis showed a statistically significant difference between selenium and placebo in the outcomes of interest: Glasgow Outcome Scale after 1 month (OR: 1.54, 95% CI [1.10, 2.15], P = 0.01) and respiratory infection (OR: 0.55, 95% CI [0.34, 0.88], P = 0.01). There is no statistically significant difference in Glasgow Outcome Scale after 3 months (OR: 1.36, 95% CI [0.97, 1.91], P = 0.07), mortality (OR: 0.76, 95% CI [0.45, 1.30], P = 0.31). Conclusion Selenium showed a promising contribution to minimizing the damage caused by brain injuries. Further studies, including randomized-controlled trials, must be conducted on the efficacy of selenium and its association with better neurological outcomes.

TL;DR: For clinicians recovery after stroke, basic elements of spontaneous neural repair, and ongoing work to augment neural repair are reviewed.

TL;DR: A modified Mobility Scale for All Stroke Phases (MSAllS) was developed and evaluated for measurement properties and clinical application, demonstrating adequate validity, reliability, and interpretability as a potential single outcome measure for physical function after stroke.

TL;DR: Recent advancements in drug delivery systems have shown promising results in targeting the blood-brain barrier, utilizing nanoparticle-based systems, focused ultrasound, and alternative routes to enhance brain drug targeting and potentially revolutionize CNS disorder treatment.

TL;DR: A valid prognosis of UE function can be made within 3 and 6 weeks in patients with mild and severe UE paresis, respectively, and a valid prediction should not be expected after 6 and 11 weeks respectively, in these groups of patients.

TL;DR: There was a remarkable uniformity in the sequences of recovery of all patients, regardless of whether sensory disturbances were present and whether the dominant or nondominant hemisphere was involved; the patients progressed from one recovery phase to the next in an orderly fashion without any of the phases being omitted.

TL;DR: This Point of View describes the problem and offers a solution in the form of definitions of compensation and recovery at the neuronal, motor performance, and functional levels within the framework of the International Classification of Functioning model.

TL;DR: Sex, handedness, and side of stroke lesion were not independent outcome predictors, and the influence of age was minimal, but a valid prognosis of aphasia could be made within 1 to 4 weeks after the stroke depending on the initial severity.